What is Biogen Inc (BIIB)?

Biogen Inc (BIIB) is a Stock on NASDAQ. The last price is Lang & Schwarz when we have a quote. Charts stay delayed daily prices.

What is the ISIN of BIIB?

The ISIN for Biogen Inc (BIIB) is US09062X1037. It trades on NASDAQ.

Is this live market data?

The displayed quote defaults to Lang & Schwarz. NASDAQ and the charts are delayed daily prices. Not investment advice.

How do I research BIIB in Blinx?

Open the terminal and ask Blinx about BIIB: business overview, recent price action, valuation, and what to watch next. Tape is the public delayed chart; the terminal adds live data and portfolio context.

BIIB · Biogen Inc — Tape

All tape

B

BIIB NASDAQ

10:59 PM

Biogen Inc has drawn market attention after news that its experimental lupus drug showed benefit against skin symptoms. The company's financial profile shows an annual revenue of $9.81 billion alongside a market capitalization of $32.63 billion. Currently, Biogen trades at a PE ratio of 38.88, with a TTM EPS of 5.65 and a free cash flow yield of 9.10%.

Based on reuters.com

1D1 day

5D5 days

1M1 month

6M6 months

YTDYear to date

1Y1 year

5Y5 years

AllAll time

seekingalpha.comOct 16, 08:28 AM
Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)
schaeffersresearch.comOct 12, 09:49 AM
3 Big Names Enjoying Renewed Analyst Backing
247wallst.comOct 12, 08:14 AM
Here Are Monday’s Top Wall Street Analyst Research Calls: Adobe, Biogen, First Solar, GoDaddy, Hubspot, Palantir Technologies, Robinhood Markets, Snowflake, TeraWulf, T-Mobile US and More
fool.comOct 11, 05:46 PM
Which Healthcare ETF Is the Better Buy: Fidelity’s Broad FHLC or Invesco’s Biotech-Focused PBE?
seekingalpha.comOct 7, 09:00 AM
Stock Picks From Seeking Alpha's September 2026 New Analysts
proactiveinvestors.comOct 6, 02:28 PM
Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says

Market cap: 32.63B USD
Dividend yield: 0.00%
P/E: 38.88
Forward P/E: 12.94
Basic EPS (TTM): 5.65 USD
EPS (FY2027E): 16.55 USD
Net income (FY): 1.29B USD
Revenue (FY): 9.81B USD
Revenue (FY2027E): 10.67B USD
FCF yield (TTM): 9.10%
Shares float: —
Beta: —
52 week high
52 week low
Volume

Ticker: BIIB
Exchange: NASDAQ
Type: Stock
Sector: —
ISIN: US09062X1037

Revenue & Net Income (5Y)

EPS & Growth (5Y)

Free Cash Flow (5Y)

Capital Returns

Operating & Net Margin (5Y)

CapEx vs. Free Cash Flow (5Y)

Capital Allocation (5Y)

R&D and SG&A Intensity (5Y)

EBITDA (5Y)

Cost of Revenue (5Y)

Market Cap (5Y)

Ask Blinx with professional market data, charts beside chat, and your portfolio context.

Ask Blinx about BIIB

Default quotes are Lang & Schwarz. NASDAQ is the delayed listing price. Charts stay daily. Not investment advice.

BIIB

B